Merck completes $10B acquisition of Verona Pharma, adding Ohtuvayre — the first new inhaled COPD therapy in over 20 years.
-Ritedose is the development partner and manufacturer of Ohtuvayre (ensifentrine)*, the first inhaled product with a novel mechanism of action in more than 20 years for the maintenance treatment of ...
Expedition Therapeutics Raises $165 Million in Oversubscribed Series A Financing to Advance Next-Generation DPP1 inhibitor ...
Merck & Co. Inc. (NYSE:MRK) is one of the best growth stocks to buy now. On October 7, Merck & Co. announced the completion ...
Acquisition aligns with Merck’s science-led business development strategy and expands pipeline and portfolio of treatments for cardio-pulmonary diseases Through this acquisition Merck will add ...
Verywell Health on MSN
Don’t Combine These COPD Medicines
Check this table to make sure you can use your COPD inhalers together Medically reviewed by Sanja Jelic, MD Most people with chronic obstructive pulmonary disease (COPD) use an inhaler every day to ...
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)-- Aptar Digital Health, part of Aptar Pharma, a global leader in drug delivery and active material science solutions and services, today announced a strategic ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback